Shaheen has completed his PhD at the age of 31 years in the field of virology from Al-Azhar University. Also, Dr. Shaheen work as researcher of molecular virology at National Research Center, Dokki, Egypt. Shaheen has eight years experience in the field of virology. To date he has published nine papers in reputed journals and three abstracts in in international conferences, most of these publications he is the first and corresponding author. Currently, Dr. Shaheen started postdoctoral training in virology field at molecular medicine department, Padova university, Italy.
Coxsackie virus B3 (CVB3) represents current major threats to public health and considers as an important viral pathogen related to viral myocarditis. We determined the antiviral properties of five extracts (methanol, chloroform, ethyl acetate, n-butanol, and aqueous ) from Cassia alata leaves in vitro. The most potent extract was selected to be tested in vivo. In vitro, the cytotoxicity effect of the extracts on GMK cells was conducted by MTT colorimetric assay. The antiviral activity of the extracts was determined in three different ways (virucidal, pre-treatment, and post-treatment) by MTT and 50% tissue culture infectious dose (TCID50) methods. In vivo, after toxicity determination, the antiviral activity of the selected extract using two safe doses was evaluated based on determination of the morbidity, mortality, heart to body weight ratio (HW/BW), activities of LDH, AST, and CK enzymes, virus titers, and necrosis in heart tissues in infected mice with CVB3. Our results demonstrated that the all extracts of C. alata showed antiviral activity against CVB3 in vitro with TI ranged from 0.2 to 12.2 and reduction in virus titers ranged from 0 log10 to 2.5 log10 where the aqueous extract was the most effective against CVB3 infection in vitro. In vivo, the aqueous extract was found to be safe at 100 mg/kg body weight and therefor for antiviral evaluation we used 100 and 50 mg/kg body weight as safe doses. Our results suggested that the aqueous extract of C. alata significantly reduced the morbidity, mortality, HW/BW, virus titers, necrosis and mononuclear cell infiltration of heart tissues at the both dosages. Also the extract showed the ability to maintain levels of LDH, AST, and CK enzymes at normal level in the treated infected mice compared with those untreated infected mice. This result suggested that the aqueous extract of C. alata may represent a potential antiviral agent to treatment CVB3 myocarditis.
I’am Hanen Boukoum Dr on Biology. I Have completed my PhD this year 2015. my research work was concentrated mainly on the study of viruses. My thesis was done in the laboratory of transmissible diseases and biologically active substances in the Faculty of Pharmacy of Monastir, Tunisia and a part of my work was made in the laboratory of Virology in Saint Eloi hospital Montpellier in France. Currently I have five publications in the JMV.
BK polyomavirus (BKPyV) is the most common pathogen in renal transplant recipients and BKPyV associated nephropathy (BKPyVAN) is one of the most significant causes of graft dysfunction and loss in renal transplant recipients. The aim of this study is to find if there is an association between the BKPyV genotypes and the BKPyVAN. A total of 72 renal transplant recipients were studied. BKPyV were detected and quantified by real-time PCR in urine and plasma. Isolates from positive urine samples were genotyped and a phylogenetic analysis was performed. In the studied population, two from the 34 BKPyV infected patients developed BKPyVAN and both have subtype I/ subgroup Ib-2. The most other patients clustered with genotype I/ subgroup Ib-2 present in 76.5% of the detected isolates. Subtype II, Subtype IV and Subtype I/subgroup Ib-1 were found in 17.5%, 3% and 3%, respectively. This study suggests that there is not a clear relationship between viral genotypes and BKPyVAN; since the majority of the asymptomatic infected patients had the subtype I/subgroup Ib-2.